all patients with hyperlipoproteinemia ( hlp ) type ii ( n = 9 ) treated with cholestyramine ( 12 g daily for 2-4 months ) displayed increased apparent biosynthesis ( 12.8 +/- 1.5 vs. 9.7 +/- 1.2 micro mol kg ( -1 ) hr ( -1 ) , mean +/- sem , p < 0.005 ) and an elevated apparent fractional turnover rate ( 0.230 +/- 0.017 vs. 0.176 +/- 0.014 hr ( -1 ) , p < 0.001 ) as determined over a 10-hr period , in spite of essentially unchanged plasma triglyceride concentrations .
C0020476
hyperlipoproteinemia
C0008402
cholestyramine